Bruker Daltonics to manufacture and distribute Isis Pharmaceuticals'
21 August 2006
Billerica, Mass. & Carlsbad, Calif., USA. Bruker
Daltonics, a subsidiary of Bruker BioSciences, and Isis Pharmaceuticals have
entered into a strategic alliance for the manufacturing and
distribution of Isis' Ibis T5000 biosensor system. The Ibis T5000, developed
by Isis' Ibis Biosciences division, is a universal biosensor system that can
simultaneously identify thousands of types of infectious organisms in a
sample, without needing to know beforehand what might be present in the
In the agreement, Bruker Daltonics will be the exclusive worldwide
manufacturer of the Ibis T5000 biosensor system, which incorporates Bruker
Daltonics' micrOTOF ESI-TOF mass spectrometer. Bruker Daltonics will also be
responsible for order processing, system installations and service in North
America, Europe and the Middle East.
In Europe and the Middle East, Bruker Daltonics will have exclusive
rights to sell Ibis T5000 systems and Ibis infectious organism
identification kits for various government applications, and non-exclusive
rights to sell to all other customers, including clinical, pharmaceutical
and academic researchers for all other applications except diagnostics.
Outside of Bruker Daltonics' exclusive market, Isis may sell Ibis T5000s and
its infectious organism identification kits.
The Ibis T5000 uses the triangulation identification for the genetic
evaluation of risks (TIGER) methodology, which is a combination of
genomics, mathematical modelling, mass spectrometry and molecular
amplification, to generate a "fingerprint" of each bacterium or virus,
allowing it to identify virtually any bacteria or virus present in a
In addition, the Ibis T5000 biosensor system can rapidly identify or
classify organisms that are newly-emerging, genetically altered or
unculturable. The Ibis T5000 biosensor works with many different types of
infectious samples from human samples, such as throat swabs or sputum, to
environmental samples, such as soil or air. The Ibis T5000 is currently
designated for Research Use Only (RUO) and has not been approved for any
regulated uses, including in vitro diagnostics.
"Utilizing our mass spectrometry instrumentation, the Ibis division
at Isis Pharmaceuticals has pioneered a universal biosensor system that
with the appropriate reagents and databases has the potential to meet
unmet infectious disease identification needs both in the government and
in important clinical and pharmaceutical research markets," said Frank
Laukien, President of Bruker Daltonics. "Our strategic alliance will
allow Ibis to take advantage of our instrument manufacturing
capabilities, global distribution channels and service network, while we
benefit from Ibis' technology expertise and the outstanding capabilities
of the Ibis T5000 biosensor system."
"This alliance is a major milestone in commercializing our Ibis T5000
biosensor system. We have been working with Bruker Daltonics for over
nine years and as the relationship has evolved, Bruker was an obvious
partner for the manufacturing, distribution and service of the Ibis
T5000 biosensor system," said Michael Treble, President of the Ibis
Biosciences division and Vice President of Isis Pharmaceuticals.
"Combining Bruker Daltonics' worldwide presence and instrument
manufacturing expertise with our proprietary infectious disease
identification technology is a key component of our commercialization
strategy for the Ibis T5000 system. We anticipate that this relationship
will immediately help us with this year's planned commercialization to
our early-access customers, and overall we expect that working with
Bruker Daltonics will expand the reach of the Ibis T5000 biosensor
system within the U.S. and overseas markets for various government and
medical research applications."